Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)’s share price dropped 6.4% during trading on Thursday . The company traded as low as $4.20 and last traded at $4.26. Approximately 602,708 shares changed hands during mid-day trading, a decline of 15% from the average daily volume of 708,052 shares. The stock had previously closed at $4.55.
BLCM has been the topic of a number of recent analyst reports. Citigroup reduced their price target on shares of Bellicum Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Thursday, August 9th. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 10th. BidaskClub upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. Finally, Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research report on Friday, November 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Bellicum Pharmaceuticals has an average rating of “Buy” and an average target price of $13.42.
The stock has a market capitalization of $197.29 million, a PE ratio of -1.50 and a beta of 1.10. The company has a debt-to-equity ratio of 0.39, a quick ratio of 8.01 and a current ratio of 8.01.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.03. The company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.07 million. On average, equities research analysts expect that Bellicum Pharmaceuticals Inc will post -2.39 EPS for the current fiscal year.
In other Bellicum Pharmaceuticals news, Director Jon P. Stonehouse acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 9th. The shares were acquired at an average cost of $4.56 per share, for a total transaction of $45,600.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $45,600. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.84% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA lifted its holdings in Bellicum Pharmaceuticals by 161.4% in the second quarter. BNP Paribas Arbitrage SA now owns 16,949 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 10,466 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Bellicum Pharmaceuticals in the third quarter valued at approximately $110,000. DAFNA Capital Management LLC acquired a new position in Bellicum Pharmaceuticals in the second quarter valued at approximately $221,000. Virtu Financial LLC lifted its holdings in Bellicum Pharmaceuticals by 266.8% in the third quarter. Virtu Financial LLC now owns 38,673 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 28,131 shares during the period. Finally, Jefferies Group LLC lifted its holdings in Bellicum Pharmaceuticals by 117.9% in the third quarter. Jefferies Group LLC now owns 46,799 shares of the biopharmaceutical company’s stock valued at $288,000 after buying an additional 25,325 shares during the period. Institutional investors and hedge funds own 56.13% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Bellicum Pharmaceuticals (BLCM) Stock Price Down 6.4%” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/12/07/bellicum-pharmaceuticals-blcm-stock-price-down-6-4.html.
About Bellicum Pharmaceuticals (NASDAQ:BLCM)
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Recommended Story: Cost of Equity For A Business, Investors
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.